Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...

Related Keywords

United States ,London ,City Of ,United Kingdom ,Mark Dransfield ,Christine Fox ,Lee Roth ,Mereo Biopharma ,Denise Scots Knight ,Ultragenyx Pharmaceutical Inc ,Translational Sciences ,Division Of Pulmonology ,Nasdaq ,Mereo Biopharma Group ,Industry Program ,Exchange Commission ,National Center ,United States Securities Exchange ,National Institutes Of Health ,Division Of Clinical Outcome Assessment ,University Of Alabama At Birmingham ,Astraeus ,Orbit Study ,Osteogenesis Imperfecta ,Additional Phase ,Deficiency Associated Lung Disease ,Biopharma Group ,Chief Executive Officer ,Deficiency Associated Lung ,Global Phase ,Ultragenyx Pharmaceutical ,Critical Care ,Clinical Outcome Assessment ,Patient Reported Outcome ,Respiratory Questionnaire ,Total Score ,Advancing Translational Sciences ,National Institutes ,Professor Mark Dransfield ,License Agreement ,Runway Guidance ,Financial Reporting ,United States Securities Act ,United States Securities Exchange Act ,Annual Report ,Biopharma Contacts ,Chief Executive ,Chief Financial ,Investor Relations Adviser ,Markets ,